Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 628
Filtrar
1.
Ars pharm ; 61(2): 63-79, abr.-jun. 2020. tab, ilus, graf
Artículo en Español | IBECS | ID: ibc-188101

RESUMEN

INTRODUCCIÓN: En diciembre de 2019, se detectaron los primeros casos de enfermedad respiratoria causada por un coronavirus emergente, al que se denominó SARS-CoV-2, que en los primeros meses de 2020 se ha extendido por todo el mundo con características de pandemia. MÉTODO: Se examinaron las publicaciones más relevantes en relación con los objetivos de la revisión. RESULTADOS: La enfermedad, conocida como COVID-19, cursa con tos, fiebre y dificultad respiratoria. Las formas más graves, que afectan principalmente a personas de edad avanzada y con determinadas comorbilidades, se manifiestan por afectación de la función respiratoria, que requiere ventilación mecánica, y síndrome de respuesta inflamatoria sistémica, que puede conducir a un choque séptico con fallo multiorgánico, y altas tasas de mortalidad. En esta revisión se examina el estado actual de conocimientos sobre las características y origen del SARS-CoV-2, su replicación, y la patogénesis, clínica, diagnóstico, tratamiento y prevención de COVID-19. CONCLUSIONES: Las características del SARS-CoV-2 y la clínica de COVID-19 son bien conocidas. La PCR es la técnica de referencia para el diagnóstico de laboratorio; se dispone de ensayos para detección de antígenos y de anticuerpos, con margen de optimización. Los protocolos de tratamiento incluyen la corrección de la respuesta inflamatoria sistémica y administración de agentes antivirales. Existen vacunas en desarrollo


INTRODUCTION: In December 2019, the first cases of respiratory disease caused by an emerging coronavirus were detected. The causative agento f the outbreak was called SARS-CoV-2, and in the first months of 2020 it spread throughout the world as a pandemic. METHOD: The most relevant publications concerned with the aims of the review were examined. RESULTS: The disease, known as COVID-19. Patients show cough, fever, and respiratory distress. The most severe forms, mainly affecting the elderly and associated with various comorbidities, are manifested by impaired respiratory function, requiring mechanical ventilation, and systemic inflammatory response syndrome, which can lead to septic shock with multi-organ failure and high mortality rates. This review examines the current state of knowledge about the characteristics and origin of SARS-CoV-2, its replication, and the pathogenesis, clinical, diagnosis, treatment, and prevention of COVID-19. CONCLUSIONS: The characteristics of SARS-CoV-2 and the clinical manifestations of COVID-19 are well known. PCR is the reference technique for laboratory diagnosis; assays for the detection of antigens and antibodies are available, with optimization possibilities. Treatment protocols include attenuation of the systemic inflammatory response and administration of antiviral agents. There are vaccines in development


Asunto(s)
Humanos , Infecciones por Coronavirus , Neumonía Viral , Betacoronavirus/patogenicidad , Pandemias , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/terapia , Neumonía Viral/diagnóstico , Neumonía Viral/prevención & control , Neumonía Viral/terapia
2.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-LISBR1.1-47374

RESUMEN

Este mapa apresenta uma visão geral da evidência sobre a aplicação das MTCI com base na caracterização de 125 estudos de revisão e estudos clínicos controlados, distribuídos em uma matriz com 57 intervenções sobre uma série de desfechos clínicos agrupados em 3 categorias: Melhora da imunidade/efeito antiviral para vírus respiratórios; Manejo complementar dos sintomas de infecções respiratórias; e Contribuições à Saúde Mental/Emocional em situações de trauma. As intervenções representam especialmente medicamentos fitoterápicos, medicina e terapias tradicionais chinesas, terapias mente-corpo como meditação e yoga, probióticos e outros suplementos nutricionais além de formulações dinamizadas da homeopatia.


Asunto(s)
Betacoronavirus , Neumonía Viral/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/prevención & control , Pandemias/prevención & control , Resultado del Tratamiento , Medicina Basada en la Evidencia/métodos , Medicina China Tradicional/métodos
3.
Recurso de Internet en Español | LIS - Localizador de Información en Salud | ID: lis-LISBR1.1-47375

RESUMEN

Este mapa presenta una visión general sobre posibles contribuciones de las MTCI a varias dimensiones de la pandemia por COVID-19. Dichas contribuciones se organizaron en tres categorías: Mejora de la inmunidad y efecto antiviral ante diferentes virus respiratorios; tratamiento complementario de los síntomas de las infecciones respiratorias; y salud mental en situaciones de crisis. Para el mapa se caracterizaron 125 estudios de revisión y estudios clínicos controlados, distribuidos en una matriz con 57 intervenciones para las tres categorías mencionadas. Las intervenciones representan especialmente medicinas herbales/ fitoterapia, medicina tradicional china, terapias de cuerpo-mente como la meditación y el yoga, probióticos y otros suplementos nutricionales además de formulaciones de homeopatía.


Asunto(s)
Betacoronavirus , Neumonía Viral/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/prevención & control , Pandemias/prevención & control , Resultado del Tratamiento , Medicina Basada en la Evidencia/métodos , Medicina China Tradicional/métodos
4.
Recurso de Internet en Inglés | LIS - Localizador de Información en Salud | ID: lis-LISBR1.1-47376

RESUMEN

This map presents an overview of the evidence on the application of TCIM based on the characterization of 125 review studies and controlled clinical studies distributed in a matrix with 57 interventions on a series of clinical outcomes grouped into 3 major categories: Improved immunity/antiviral effect for respiratory viruses; Complementary management of symptoms of respiratory infections; and Mental health. The interventions represent especially herbal medicines, traditional Chinese medicine and therapies, mind-body therapies like meditation and yoga, probiotics and other nutritional supplements besides homeopathy formulations.


Asunto(s)
Betacoronavirus , Neumonía Viral/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/prevención & control , Pandemias/prevención & control , Resultado del Tratamiento , Medicina Basada en la Evidencia/métodos , Medicina China Tradicional/métodos
5.
Goiânia; SES-GO; maio 2020. 1-36 p. ilus, tab.
No convencional en Portugués | LILACS, Coleciona SUS, CONASS, SES-GO | ID: biblio-1096093

RESUMEN

O surto da doença respiratória causada pelo novo coronavírus (SARS-CoV-2) aconteceu na cidade de Wuhan, capital da província de Hubei, na China, em dezembro de 2019, a qual disseminou-se de forma acelerada e, logo, atingiu mais de uma centena de países dos cinco continentes. Em 12 de março de 2020, a situação foi caracterizada como pandemia pela Organização Mundial de Saúde (OMS, 2020). Em razão da disseminação o do Coronavírus pelo mundo, o Ministério da Saúde declarou Emergência de Saúde Pública de Importância Nacional (ESPIN) em decorrência da infecção pelo novo coronavírus (COVID-19) e estabeleceu o Centro de Operações de Emergência em Saúde Pública (COE-COVID-19) como mecanismo de gestão coordenada da resposta à ESPIN no país (BRASIL, 2020a). Seguindo a linha mundial, o Ministério da Saúde elaborou e publicou "Plano de Contingência Nacional para Infecção Humana pelo Novo Coronavírus COVID-19" para organizar a detecção, monitoramento e resposta dos serviços de saúde à doença (BRASIL, 2020b). O Estado de Goiás instituiu o Centro de Operações Estratégicas de Saúde Pública (COE) em 18 de fevereiro de 2020 (GOIÁS, 2020a). E, seguindo as orientações nacionais, propõe o presente PLANO ESTADUAL DE CONTINGÊNCIA PARA O ENFRENTAMENTO DA DOENÇA PELO CORONAVÍRUS (COVID-19), a fim de organizar e fortalecer as políticas públicas de saúde, visto que, para que atinjam eficácia e eficiência, é necessário atuação conjunta e ordenada dos entes federados, bem como dos setores públicos e privados.


The outbreak of respiratory disease caused by the new coronavirus (SARS-CoV-2) occurred in Wuhan city, capital of Hubei province, China, in December 2019, which spread rapidly and thus reached more than a hundred countries on five continents. On March 12, 2020, the situation was characterized as a pandemic by the World Health Organization (WHO, 2020). Due to the spread of Coronavirus around the world, the Ministry of Health declared a Public Health Emergency of National Importance (ESPIN) due to infection by the new coronavirus (COVID-19) and established the Center for Emergency Operations in Public Health (COE-COVID-19) as a mechanism for coordinated management of the response to ESPIN in the country (BRASIL, 2020a). Following the global line, the Ministry of Health elaborated and published "National Contingency Plan for Human Infection by the New Coronavirus COVID-19" to organize the detection, monitoring and response of health services to the disease (BRASIL, 2020b). The State of Goiás established the Center for Strategic Operations of Public Health (COE) on February 18, 2020 (GOIÁS, 2020a). And, following the national guidelines, it proposes this State CONTINGENCY PLAN FOR COPING WITH CORONAVIRUS DISEASE (COVID-19), in order to organize and strengthen public health policies, since, in order to achieve effectiveness and efficiency, joint and orderly action of federal entities, as well as public and private sectors, is necessary.


Asunto(s)
Humanos , Masculino , Femenino , Embarazo , Recién Nacido , Lactante , Preescolar , Niño , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/transmisión
7.
Brasília; Brasil. Ministério da Saúde; maio 2020. ilus, tab.
No convencional en Portugués | LILACS, Coleciona SUS | ID: biblio-1095920

RESUMEN

No fim de 2019, o Novo Coronavírus foi nomeado como SARS-CoV-2. Este Novo Coronavírus produz a doença classificada como COVID-19, sendo agente causador de uma série de casos de pneumonia na cidade de Wuhan (China) [1]. Ainda não há informações plenas sobre a história natural, nem medidas de efetividade inquestionáveis para manejo clínico dos casos de infecção humana pelo SARS-CoV-2, restando ainda muitos detalhes a serem esclarecidos [1]. No entanto, sabe-se que o vírus tem alta transmissibilidade e provoca uma síndrome respiratória aguda que varia de casos leves ­ cerca de 80% ­ a casos muito graves com insuficiência respiratória ­entre 5% e 10% dos casos. Sua letalidade varia, principalmente, conforme a faixa etária (Quadro 1) e condições clínicas associadas. Portanto, é necessário agir. Para esse fim, as melhores e mais recentes evidências foram utilizadas na redação deste documento. Pela dinâmica da epidemia e da produção de conhecimento associada a ela, as informações podem sofrer alterações conforme avance o conhecimento sobre a doença. Dessa forma, este protocolo específico para serviços de Atenção Primária à Saúde / Estratégia Saúde da Família (APS/ESF) nos cenários de transmissão comunitária vai ser atualizado sempre que necessário. A APS/ESF é a porta de entrada do Sistema Único de Saúde. Durante surtos e epidemias, a APS/ ESF tem papel fundamental na resposta global à doença em questão. A APS/ESF oferece atendimento resolutivo, além de manter a longitudinalidade e a coordenação do cuidado em todos os níveis de atenção à saúde, com grande potencial de identificação precoce de casos graves que devem ser manejados em serviços especializados. O objetivo deste documento é definir o papel dos serviços de APS/ESF no manejo e controle da infecção COVID-19, bem como disponibilizar os instrumentos de orientação clínica para os profissionais que atuam na porta de entrada do SUS a partir da transmissão comunitária de COVID-19 no Brasil. Considerando a existência de fase de transmissão comunitária da COVID-19, é imprescindível que os serviços de APS/ESF trabalhem com abordagem sindrômica do problema, não exigindo mais a identificação do fator etiológico por meio de exame específico. Desta forma, este protocolo foca na abordagem clínica da Síndrome Gripal e da Síndrome Respiratória Aguda Grave (SRAG), independentemente do agente etiológico. Como é de conhecimento de todos, múltiplos agentes virais são responsáveis por essas duas síndromes, sendo o vírus da Influenza o de maior magnitude nos últimos anos. Entretanto, há evidências e dados internacionais indicando que a transcendência da COVID-19 pode superar a da Influenza. Portanto, a abordagem pragmática deste protocolo unifica as condutas referentes a esses dois grupos de vírus.


Asunto(s)
Humanos , Atención Primaria de Salud/normas , Protocolos Clínicos/normas , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/terapia , Infecciones por Coronavirus/transmisión , Aislamiento de Pacientes/métodos , Brasil , Infecciones por Coronavirus/prevención & control
10.
J Korean Med Sci ; 35(18): e176, 2020 May 11.
Artículo en Inglés | MEDLINE | ID: mdl-32383371

RESUMEN

The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV-2 and neutralize its aggressive actions on multiple organ systems. Protective cross-reactivity of antibodies against measles and other known viral infections has been postulated, primarily as a result of the initial observations of asymptomatic and mild COVID-19 in children. Uncontrolled case series have demonstrated virus-neutralizing effect of convalescent plasma, supporting its efficiency at early stages of contracting SARS-CoV-2. Given the variability of the virus structure, the utility of convalescent plasma is limited to the geographic area of its preparation, and for a short period of time. Intravenous immunoglobulin may also be protective in view of its nonspecific antiviral and immunomodulatory effects. Finally, human monoclonal antibodies may interact with some SARS-CoV-2 proteins, inhibiting the virus-receptor interaction and prevent tissue injury. The improved understanding of the host antiviral responses may help develop safe and effective immunotherapeutic strategies against COVID-19 in the foreseeable future.


Asunto(s)
Infecciones por Coronavirus/terapia , Coronavirus , Inmunoglobulinas Intravenosas/uso terapéutico , Neumonía Viral/terapia , Anticuerpos Antivirales/sangre , Betacoronavirus , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/epidemiología , Humanos , Inmunización Pasiva , Pandemias , Neumonía Viral/epidemiología
11.
Basic Res Cardiol ; 115(4): 36, 2020 05 12.
Artículo en Inglés | MEDLINE | ID: mdl-32399655

RESUMEN

There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19-75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43-2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89-1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26-0.82 × 103/µl) but had increased in three of these five patients at last follow-up (range 0.23-1.02 × 103/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.


Asunto(s)
Tratamiento Basado en Trasplante de Células y Tejidos , Ensayos de Uso Compasivo , Infecciones por Coronavirus/terapia , Miocardio/citología , Neumonía Viral/terapia , Células Madre/citología , Anciano , Betacoronavirus , Biomarcadores/sangre , Enfermedad Crítica/terapia , Femenino , Ferritinas/sangre , Humanos , Infusiones Intravenosas , Los Angeles , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Pandemias , Adulto Joven
12.
Euro Surveill ; 25(18)2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32400362

RESUMEN

Data on features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children and adolescents are scarce. We report preliminary results of an Italian multicentre study comprising 168 laboratory-confirmed paediatric cases (median: 2.3 years, range: 1 day-17.7 years, 55.9% males), of which 67.9% were hospitalised and 19.6% had comorbidities. Fever was the most common symptom, gastrointestinal manifestations were frequent; two children required intensive care, five had seizures, 49 received experimental treatments and all recovered.


Asunto(s)
Enfermedad Crónica/epidemiología , Coinfección/epidemiología , Infecciones por Coronavirus/diagnóstico , Coronavirus/aislamiento & purificación , Pandemias/prevención & control , Neumonía Viral/diagnóstico , Adolescente , Antivirales/uso terapéutico , Betacoronavirus , Niño , Preescolar , Técnicas de Laboratorio Clínico , Coinfección/virología , Comorbilidad , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Diarrea/etiología , Brotes de Enfermedades , Heces/virología , Femenino , Fiebre/etiología , Hospitales Pediátricos , Humanos , Huésped Inmunocomprometido , Lactante , Recién Nacido , Italia/epidemiología , Masculino , Ventilación no Invasiva/métodos , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Inhibidores de Proteasas/uso terapéutico , Estudios Retrospectivos , Síndrome Respiratorio Agudo Grave/diagnóstico , Síndrome Respiratorio Agudo Grave/epidemiología , Síndrome Respiratorio Agudo Grave/terapia , Resultado del Tratamiento
13.
Scand J Trauma Resusc Emerg Med ; 28(1): 37, 2020 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-32404141

RESUMEN

The COVID-19 crisis is an unprecedented event. It is therefore essential for dispatch centres to share their experiences while the crisis is underway, similar to hospitals, so that we will all benefit from feedback.This letter to the editor describes the Lausanne dispatch centre response to COVID-19 and the lessons learned so far.


Asunto(s)
Infecciones por Coronavirus/terapia , Asesoramiento de Urgencias Médicas , Neumonía Viral/terapia , Infecciones por Coronavirus/epidemiología , Humanos , Pandemias , Neumonía Viral/epidemiología
14.
Eur J Med Res ; 25(1): 16, 2020 May 13.
Artículo en Inglés | MEDLINE | ID: mdl-32404189

RESUMEN

The rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available.


Asunto(s)
Betacoronavirus/inmunología , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/terapia , Inmunización Pasiva , Neumonía Viral/inmunología , Neumonía Viral/terapia , Humanos , Inmunización Pasiva/tendencias , Pandemias
15.
Can Fam Physician ; 66(5): 332-334, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32404451

RESUMEN

Question Coronavirus disease 2019 (COVID-19) is affecting millions of people worldwide. It seems that it affects mostly adults older than 40 years of age, and the death rate is highest for older individuals in the population. What should I tell parents worried about their children contracting the coronavirus (SARS-CoV-2) causing COVID-19, and what symptoms should I look for to determine if there is a need to test for the virus?Answer The COVID-19 global pandemic affects all ages. Severe respiratory manifestations have been the mainstay of illness in adults, with what seems to be rapid deterioration necessitating mechanical ventilation. Only 5% of those tested and found to have COVID-19 have been younger than 19 years, possibly owing to limited testing, as the symptoms in children are usually mild. Symptoms in children include fever, dry cough, rhinorrhea, sore throat, and fatigue, and in 10% diarrhea or vomiting. Rarely dyspnea or hypoxemia were also described. Blood tests and imaging have been shown to be of little value in children and should only be ordered for those in whom you would normally order these investigations for viral-like illness. No specific therapy is available and supportive care with rest, fluids, and antipyretics for children is the recommended approach. Ibuprofen or acetaminophen for fever and pain can be given. Antiviral and immunomodulatory treatment is not recommended at this time for otherwise healthy children, and corticosteroids should also not be used. Children with immunocompromised states should be isolated and avoid contact with others.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Salud Global , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Niño , Servicios de Salud del Niño , Técnicas de Laboratorio Clínico , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/fisiopatología , Humanos , Padres/psicología , Neumonía Viral/diagnóstico , Neumonía Viral/fisiopatología , Evaluación de Síntomas
16.
Front Med ; 14(2): 232-248, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32405974

RESUMEN

Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/terapia , Neumonía Viral/terapia , Antivirales/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Humanos , Terapia por Inhalación de Oxígeno , Pandemias , Respiración
17.
MMWR Morb Mortal Wkly Rep ; 69(19): 606-610, 2020 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-32407303

RESUMEN

On March 17, 2020, a member of a Skagit County, Washington, choir informed Skagit County Public Health (SCPH) that several members of the 122-member choir had become ill. Three persons, two from Skagit County and one from another area, had test results positive for SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19). Another 25 persons had compatible symptoms. SCPH obtained the choir's member list and began an investigation on March 18. Among 61 persons who attended a March 10 choir practice at which one person was known to be symptomatic, 53 cases were identified, including 33 confirmed and 20 probable cases (secondary attack rates of 53.3% among confirmed cases and 86.7% among all cases). Three of the 53 persons who became ill were hospitalized (5.7%), and two died (3.7%). The 2.5-hour singing practice provided several opportunities for droplet and fomite transmission, including members sitting close to one another, sharing snacks, and stacking chairs at the end of the practice. The act of singing, itself, might have contributed to transmission through emission of aerosols, which is affected by loudness of vocalization (1). Certain persons, known as superemitters, who release more aerosol particles during speech than do their peers, might have contributed to this and previously reported COVID-19 superspreading events (2-5). These data demonstrate the high transmissibility of SARS-CoV-2 and the possibility of superemitters contributing to broad transmission in certain unique activities and circumstances. It is recommended that persons avoid face-to-face contact with others, not gather in groups, avoid crowded places, maintain physical distancing of at least 6 feet to reduce transmission, and wear cloth face coverings in public settings where other social distancing measures are difficult to maintain.


Asunto(s)
Betacoronavirus/aislamiento & purificación , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/transmisión , Brotes de Enfermedades , Neumonía Viral/epidemiología , Neumonía Viral/transmisión , Canto , Adulto , Anciano , Anciano de 80 o más Años , Infecciones por Coronavirus/mortalidad , Infecciones por Coronavirus/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/mortalidad , Neumonía Viral/terapia , Factores de Riesgo , Washingtón/epidemiología
18.
J Exp Med ; 217(6)2020 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-32353870

RESUMEN

The novel 2019 strain of coronavirus is a source of profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has a relatively high mortality rate, the reasons for which are not entirely clear. Furthermore, treatment options for COVID-19 infection are currently limited. In this Perspective, we explore the contributions of the innate and adaptive immune systems to both viral control as well as toxicity during COVID-19 infections and offer suggestions to both understand and therapeutically modulate anti-COVID immunity.


Asunto(s)
Betacoronavirus/inmunología , Infecciones por Coronavirus/inmunología , Neumonía Viral/inmunología , Inmunidad Adaptativa/efectos de los fármacos , Inmunidad Adaptativa/inmunología , Betacoronavirus/efectos de los fármacos , Betacoronavirus/patogenicidad , Infecciones por Coronavirus/patología , Infecciones por Coronavirus/terapia , Síndrome de Liberación de Citoquinas/inmunología , Síndrome de Liberación de Citoquinas/patología , Síndrome de Liberación de Citoquinas/terapia , Humanos , Hipoxia/patología , Hipoxia/terapia , Inmunidad Innata/efectos de los fármacos , Inmunidad Innata/inmunología , Inflamación/inmunología , Inflamación/patología , Inflamación/terapia , Interleucina-6/antagonistas & inhibidores , Interleucina-6/inmunología , Linfopenia/inmunología , Linfopenia/patología , Linfopenia/terapia , Macrófagos/inmunología , Macrófagos/patología , Coronavirus del Síndrome Respiratorio de Oriente Medio/inmunología , Coronavirus del Síndrome Respiratorio de Oriente Medio/patogenicidad , Pandemias , Neumonía Viral/patología , Neumonía Viral/terapia , Respiración Artificial , Síndrome de Dificultad Respiratoria del Adulto/patología , Síndrome de Dificultad Respiratoria del Adulto/terapia , Virus del SRAS/inmunología , Virus del SRAS/patogenicidad
20.
Enferm Intensiva ; 31(2): 82-89, 2020.
Artículo en Inglés, Español | MEDLINE | ID: mdl-32360022

RESUMEN

In January 2020, the Chinese authorities identified a new virus of the Coronaviridae family as the cause of several cases of pneumonia of unknown aetiology. The outbreak was initially confined to Wuhan City, but then spread outside Chinese borders. On 31 January 2020, the first case was declared in Spain. On 11 March 2020, The World Health Organization (WHO) declared the coronavirus outbreak a pandemic. On 16 March 2020, there were 139 countries affected. In this situation, the Scientific Societies SEMICYUC and SEEIUC, have decided to draw up this Contingency Plan to guide the response of the Intensive Care Services. The objectives of this plan are to estimate the magnitude of the problem and identify the necessary human and material resources. This is to provide the Spanish Intensive Medicine Services with a tool to programme optimal response strategies.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Cuidados Críticos/organización & administración , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Humanos , España/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA